Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Biomarker
1.1.2. End Use
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Biomarker outlook
2.2.2. End Use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Rare Biomarkers Specimen Collection And Stabilization Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Rare Biomarkers Specimen Collection And Stabilization Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Rare Biomarkers Specimen Collection And Stabilization: Biomarker Estimates & Trend Analysis
4.1. Rare Biomarkers Specimen Collection And Stabilization Market: Key Takeaways
4.2. Rare Biomarkers Specimen Collection And Stabilization Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Circulating Cell Free DNA (ccfDNA)
4.3.1. Circulating cell free DNA (ccfDNA) market estimates and forecasts, 2018 to 2030 (USD Billion)
4.4. Circulating Tumor Cells (CTCs)
4.4.1. Circulating tumor cells (CTCs) market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5. Exosomes/Extracellular Vesicles
4.5.1. Exosomes/Extracellular vesicles market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.2. Product
4.5.2.1. Product market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.2.2. Isolation kits & reagents
4.5.2.2.1. Isolation kits & reagents market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.2.3. Blood collection tubes
4.5.2.3.1. Blood collection tubes market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.2.4. Systems
4.5.2.4.1. Systems market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.3. Specimen type
4.5.3.1. Specimen type market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.3.2. Serum/Plasma
4.5.3.2.1. Serum/Plasma market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.3.3. Others
4.5.3.3.1. Others market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.4. Nucleic acid & other biomolecules
4.5.4.1. Nucleic acid & other biomolecules market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.4.2. RNA
4.5.4.2.1. RNA market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.4.3. DNA
4.5.4.3.1. DNA market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.4.4. Others
4.5.4.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5. Application
4.5.5.1. Application market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.2. NIPT
4.5.5.2.1. NIPT market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.3. Oncology
4.5.5.3.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.3.2. Research
4.5.5.3.2.1. Research market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.3.3. Diagnostics
4.5.5.3.3.1. Diagnostics market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.3.3.2. Screening
4.5.5.3.3.2.1. Screening market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.3.3.3. Treatment monitoring
4.5.5.3.3.3.1. Treatment Monitoring market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.4. Transcriptomics
4.5.5.4.1. Transcriptomics market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.5. Pharmacogenomics
4.5.5.5.1. Pharmacogenomics market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.6. Transplant rejection
4.5.5.6.1. Transplant rejection market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.7. Population screening
4.5.5.7.1. Population screening market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.8. Cardiovascular diseases
4.5.5.8.1. Cardiovascular diseases market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.5.9. Other applications
4.5.5.9.1. Other applications market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6. Circulating Cell Free RNA (ccfRNA) / miRNA
4.6.1. Circulating cell free RNA (ccfRNA) / miRNAmarket estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.2. Product
4.6.2.1. Product market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.2.2. Isolation kits & reagents
4.6.2.2.1. Isolation kits & reagents market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.2.3. Blood collection tubes
4.6.2.3.1. Blood collection tubes market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3. Application
4.6.3.1. Application market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3.2. NIPT
4.6.3.2.1. NIPT market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3.3. Oncology
4.6.3.3.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3.3.2. Research
4.6.3.3.2.1. Research market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3.3.3. Diagnostics
4.6.3.3.3.1. Diagnostics market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3.4. Transcriptomics
4.6.3.4.1. Transcriptomics market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3.5. Pharmacogenomics
4.6.3.5.1. Pharmacogenomics market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3.6. Transplant rejection
4.6.3.6.1. Transplant rejection market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3.7. Population screening
4.6.3.7.1. Population screening market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3.8. Cardiovascular diseases
4.6.3.8.1. Cardiovascular diseases market estimates and forecasts, 2018 to 2030 (USD Billion)
4.6.3.9. Other applications
4.6.3.9.1. Other applications market estimates and forecasts, 2018 to 2030 (USD Billion)
Chapter 5. Rare Biomarkers Specimen Collection And Stabilization: End Use Estimates & Trend Analysis
5.1. Rare Biomarkers Specimen Collection and Stabilization Market: Key Takeaways
5.2. Rare Biomarkers Specimen Collection and Stabilization Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Research
5.3.1. Research market estimates and forecasts, 2018 to 2030 (USD Billion)
5.3.2. Research labs/CROs
5.3.2.1. Research labs/CROs market estimates and forecasts, 2018 to 2030 (USD Billion)
5.3.3. Academic institutes
5.3.3.1. Academic institutes market estimates and forecasts, 2018 to 2030 (USD Billion)
5.4. Diagnostics
5.4.1. Diagnostics market estimates and forecasts, 2018 to 2030 (USD Billion)
5.4.2. Laboratories
5.4.2.1. Laboratories market estimates and forecasts, 2018 to 2030 (USD Billion)
5.4.3. Hospitals
5.4.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Billion)
5.4.4. Prenatal clinics
5.4.4.1. Prenatal clinics market estimates and forecasts, 2018 to 2030 (USD Billion)
Chapter 6. Rare Biomarkers Specimen Collection And Stabilization Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Rare Biomarkers Specimen Collection And Stabilization Market by Region: Key Takeaway
6.3. North America
6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.4.6. Denmark
6.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.4.7. Sweden
6.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.4.8. Norway
6.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.7.2. Saudi Arabia
6.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. QIAGEN
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Charles River Laboratories
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. F. Hoffmann-La Roche Ltd
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Thermofischer Scientific Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Eurofins Scientific
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. PerkinElmer Inc.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Bio-Rad Laboratories, Inc.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Agilent Technologies, Inc
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Merck KGaA
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Siemens Healthcare GmbH
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer